Wegovy in Egypt: the short answer before the details
Wegovy is the brand name of semaglutide at the dose designed for weight management. It is a once-weekly injection used alongside a reduced-calorie diet and more physical activity. The European Medicines Agency (EMA) authorised it in the EU on 6 January 2022 for adults with a BMI of 30 or more, or 27 to under 30 with a weight-related condition such as diabetes, high blood pressure or sleep apnoea [1, 2]. This article is written for adults.
In Egypt, the Egyptian Drug Authority (EDA) has published a public assessment report for Wegovy dated 12/05/2025. The applicant is the Novo Nordisk scientific office in Egypt and the registration type is listed as "EMA approved" [3]. This is an assessment report, not a registration certificate, and it carries no registration number or date of pharmacy availability. So the safe statement is that an official assessment is published; the current registration status and actual availability are for a licensed pharmacist or the EDA to confirm [3].
The practical summary: Wegovy can be a medical option for some people after assessment, and the trials show strong results, but it is not a quick fix and does not replace food and movement. Part of the weight returns if the medicine is stopped without a plan [8, 12]. The rest of this page covers who may discuss it with a doctor, the real trial numbers, side effects, comparison with alternatives, and follow-up. There are no doses and no prices, because the dose is set by the prescriber alone. For more on this, see our guide on the Mounjaro in Egypt guide.
How semaglutide works in the body
Semaglutide imitates a natural hormone called GLP-1 that the body releases after eating. It acts on brain areas that regulate hunger and fullness, so people usually feel full sooner and think about food less [6]. It also slows stomach emptying, which explains the longer feeling of fullness and part of the digestive side effects discussed below [4, 6].
The key point is that the medicine makes it easier to stick to a suitable eating plan, but it does not create the plan for you. The trials were all run with a reduced-calorie diet and physical activity, and WHO guidance says these medicines are best offered with structured behavioural support, not alone [7, 8]. If food is low in protein or there is no movement, the body can lose muscle along with fat, which is why muscle protection is part of the plan from day one.
In its December 2025 guideline, WHO made a conditional recommendation for long-term use of GLP-1 medicines in adults with obesity, excluded pregnant women, and described obesity as a chronic condition that needs continuing care rather than a short course [7]. That changes expectations: you are starting a treatment relationship with a clinician, not just buying a product.
Who may discuss Wegovy with a doctor
The main official yardstick is body mass index (BMI): 30 or more, or 27 to under 30 together with a weight-related condition such as type 2 diabetes, high blood pressure or sleep apnoea [1, 6]. But the number alone is not the decision. The doctor looks at medical history, current medicines, previous weight-loss attempts, and whether you are ready for regular follow-up [6].
People for whom the idea is usually discussed include someone who has seriously tried diet and activity but could not reach or hold a healthy weight; someone with obesity plus diabetes, high blood pressure or fatty liver; and someone with existing heart disease and obesity, since the SELECT trial was done in exactly that group [9]. If you want a few kilos off for an occasion or summer and your BMI is in the normal range, the professional answer is usually no, because a small benefit does not justify the risks.
For the wider picture of who suits weight-loss injections in general, ask us at the consultation [6]. The first visit with us covers weight, measurements and tests as needed, and then we decide together whether the medicine fits and whether something should be treated first, such as nutritional deficiency or an undiagnosed eating disorder.
What the trials actually showed
The core trial is STEP 1, published in NEJM in 2021: 1,961 adults with obesity or overweight and without diabetes, followed for 68 weeks. Mean weight change was a 14.9% reduction with semaglutide versus 2.4% with placebo, a difference of 12.4 percentage points. Weight loss of at least 5% was reached by 86.4% versus 31.5%, and of at least 15% by 50.5% versus 4.9% [8]. In kilograms the loss was 15.3 kg versus 2.6 kg [8].
STEP 5 followed 304 participants for 104 weeks (two years) and found a 15.2% loss versus 2.6% with placebo, so the result stayed in place beyond the first year while the medicine continued. In the same trial, gastrointestinal events were reported by 82.2% versus 53.9% [11]. A strong result is not free.
STEP 8 compared weekly semaglutide with daily liraglutide (Saxenda) in 338 participants over 68 weeks: a 15.8% loss versus 6.4%, which is why clinicians often favour the weekly option in many cases [13]. If that comparison matters to you, the Saxenda page covers it in full.
A word of honesty: these are averages, not promises. Some people lost more, some less, and some did not continue because of side effects. All of these trials describe people followed by a medical team with diet and activity support, not people injecting on their own [8, 11]. For more on this, see our guide on Saxenda versus weekly weight-loss injections.
Wegovy and heart protection: the SELECT trial
This is what sets Wegovy apart from most weight-loss medicines. The SELECT trial (Lincoff et al., NEJM 2023) included 17,604 patients aged 45 or older with established cardiovascular disease and a BMI of 27 or more, without diabetes. The main cardiovascular event (heart attack, stroke or cardiovascular death) occurred in 6.5% with semaglutide versus 8.0% with placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90) [9].
On that basis, the current FDA label for Wegovy lists a reduction in the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity [4]. That means the decision for people with heart disease differs from that of someone seeking cosmetic weight loss.
But there is a second side: in the same trial, permanent discontinuation because of adverse events happened in 16.6% on the medicine versus 8.2% on placebo [9]. So the heart benefit is proven for a defined group; it does not mean anyone should start the medicine to protect their heart. If you have heart disease, the decision is made together with your cardiologist and nutrition team.
Side effects and who should stay away from Wegovy
The most common side effects (in more than 1 in 10 people), according to the European agency, are headache, nausea, vomiting, diarrhoea, constipation and stomach pain [1]. They are usually mild to moderate, show up more in the early period of treatment and tend to ease with time [6]. They can return after a dose increase, which is discussed with the doctor rather than solved by changing the dose yourself.
Some people should not take it at all. The FDA label carries a boxed warning about thyroid C-cell tumours, and the medicine is contraindicated if you or your family have medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) [4, 6]. It must not be used in pregnancy or when planning pregnancy, and is not recommended while breastfeeding [6]. Pregnant women are also excluded from the WHO recommendation [7].
Tell the doctor if you have had pancreatitis, gallstones or gallbladder problems, kidney impairment, diabetic eye complications, or if you take insulin or a sulfonylurea, because the risk of low blood sugar rises [4]. If you are having anaesthesia or an endoscopy, tell the team you take the medicine, because of the risk of stomach contents entering the lungs [4].
Signs that call for stopping and contacting the team immediately, or going to emergency care: severe persistent abdominal pain that may spread to the back with vomiting, pain in the upper right abdomen with yellowing, a neck lump or swelling or trouble swallowing, severe vomiting and diarrhoea with dehydration and little urine, or any change in vision [4, 5]. Never start or stop a medicine on your own. More detail is on the red-flags page. For more on this, see our guide on serious side effects and red flags.
Wegovy or Mounjaro: a calm comparison
This is one of the most frequent questions. The main difference is that Wegovy contains semaglutide (which imitates GLP-1 only), while Mounjaro contains tirzepatide, which imitates both GLP-1 and GIP. The strongest head-to-head comparison is SURMOUNT-5 (Aronne et al., NEJM 2025): 751 participants without diabetes over 72 weeks, with a 20.2% loss on tirzepatide versus 13.7% on semaglutide, and waist circumference down 18.4 cm versus 13.0 cm [14]. The trial was open-label and funded by the maker of Mounjaro, so read the figure with care [14].
A bigger number does not mean Mounjaro is the right choice for everyone. The decision also depends on digestive tolerance, heart history (the SELECT evidence is strong for Wegovy in that group [9]), diabetes, local registration and availability, and whether you tolerated a medicine before. There is a detailed article comparing Ozempic, Wegovy and Mounjaro, and a full guide to Mounjaro in Egypt.
If you are already on Wegovy and are uncomfortable or your result has stalled, switching to Mounjaro is a decision made with the doctor in defined steps, not something to swap on your own. That topic has its own page. For comparison, Saxenda (liraglutide) is daily, and in STEP 8 it produced a smaller loss than the weekly option [13]. For more on this, see our guide on the differences between Ozempic, Wegovy and Mounjaro. For more on this, see our guide on switching from Wegovy to Mounjaro.
If you stop the medicine: what happens to weight
This is the most important question before starting. In the STEP 4 trial, participants who took the medicine for 20 weeks and then continued to week 68 lost a further 7.9% of weight, while those switched to placebo gained 6.9% [10]. In the STEP 1 extension after withdrawal (327 participants), people regained 11.6 percentage points of the weight they had lost within a year, roughly two-thirds of the loss [12].
The meaning is simple: the medicine works while it is on board, and appetite returns when it stops. That is not a personal failure; it is how obesity behaves as a chronic condition, and it is also why WHO speaks about long-term care [7, 12]. Nobody should be surprised if the doctor discusses a plan for the stage after the medicine from the start.
The plan we work on is enough protein, resistance exercise, regular sleep, and learning a way of eating that fits your life. All of that is built during treatment, not after it. On the other side, some people need to reduce or stop because of side effects, and that decision is made with the prescriber [10]. We follow you online between visits.
How to make sure the product is genuine and from a licensed source
This medicine is not something to buy from an advertisement, a social media page or a delivery contact. The safe rule: it is prescribed after a consultation when suitable, and bought from a licensed pharmacy with a prescription. If someone offers a product at a strange price or without a prescription, treat it as a warning sign [3].
Before accepting any pack: ask the licensed pharmacist about the product's registration status, read the leaflet inside, and compare the brand name, the active ingredient (semaglutide) and the manufacturer details. Because registration status changes, use the Egyptian Drug Authority's report and its source as the reference rather than advertising claims [3]. Using a pack you are unsure about risks a wrong dose or an unknown ingredient.
This is not specific to Wegovy. The same rule applies to every GLP-1 medicine, and the details are in the Mounjaro in Egypt guide.
The first visit and follow-up with us
The consultation with Dr Shimaa Fouad (a physician and clinical and therapeutic nutrition specialist, ESPEN member, with more than 18 years of experience) starts with your medical history, medicines and tests, and then we decide together whether a medicine is needed at all or whether nutrition and follow-up are enough. If the medicine is suitable, it is prescribed after the consultation and bought from a licensed pharmacy with a prescription.
Follow-up includes weight and measurements, tracking symptoms, securing protein and protecting muscle, and agreeing when to review and when to stop. If any of the red-flag symptoms above appear, contact us or go to emergency care immediately [4, 5].
Locations: the Maadi branch, 14 El-Mokhtar St, off El-Nasr St, behind QNB, New Maadi, on Saturday, Monday and Tuesday. The Fifth Settlement branch: CMC Medical Mall, 4th floor, North 90th St, behind the Air Force Specialized Hospital, on Wednesday from 3:30 to 8 pm only, with Dr Shimaa Fouad there. Schedules can change, so confirm when you book.
Cost: ask on WhatsApp at 010 4066 1893 and the team will tell you the cost before you book. You can also start with a message about your case before any visit. When you are ready: book a consultation with the medical team.
